Qualigen Therapeutics (NASDAQ:AIXC) Trading Down 0.7% – Time to Sell?

Shares of Qualigen Therapeutics, Inc. (NASDAQ:AIXC) fell 0.7% during mid-day trading on Monday . The company traded as low as $1.3150 and last traded at $1.35. 25,224 shares were traded during trading, a decline of 57% from the average session volume of 58,966 shares. The stock had previously closed at $1.36.

Wall Street Analyst Weigh In

Separately, Weiss Ratings began coverage on shares of Qualigen Therapeutics in a report on Monday, January 26th. They set a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Qualigen Therapeutics Price Performance

The firm has a 50-day moving average of $1.24. The company has a market cap of $25.06 million, a P/E ratio of -0.16 and a beta of 0.31.

Qualigen Therapeutics (NASDAQ:AIXC) last posted its quarterly earnings data on Monday, March 30th. The company reported ($3.76) earnings per share for the quarter.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.